Menu Search
Charts
From 02/05/2022 our Markets Data content will no longer be free to read. To continue to get full access, subscribe now and receive 25% off.
Learn moreSubscribe now
Equities

argenx SE

ARGX:VIE

argenx SE

Actions
  • Price (EUR)617.00
  • Today's Change-7.40 / -1.19%
  • Shares traded0.00
  • 1 Year change+71.29%
  • Beta--
Data delayed at least 15 minutes, as of Feb 14 2025.
More ▼
Take Action
Participate in the 2025 Stockpicking Contest
Long or short five stocks and compete to have the highest return by the end of the year.
Choose your picksChoose your picks

Profile data is unavailable for this security.

About the company

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.

  • Revenue in EUR (TTM)1.80bn
  • Net income in EUR-39.02m
  • Incorporated2008
  • Employees1.15k
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.